Speaker

Dr. Yaning Wang is the Founder and CEO of Rui Ning Kang Pharma, providing consulting service for new drug discovery and development, dose optimization, trial design, biomarker/surrogate/clinical endpoints justification, regulatory interactions, IND/NDA/BLA package preparation, asset and company evaluation, and license in/out negotiation. Between 2021 and 2024, he was the CEO of Createrna, a clinical-stage biopharmaceutical company developing novel therapeutics for multiple diseases. Under his leadership, 500 million RMB was raised during a capital-winter period and multiple billion-dollar license-out deals were achieved. Before 2021, he was the Director of the Division of Pharmacometrics at US FDA and oversaw reviews, research projects, and policy development for all disease areas. Before joining the FDA, Dr. Wang received his Ph.D. in Pharmaceutics and a master’s degree in Statistics from the University of Florida in 2003. He also obtained a master’s degree in Biochemistry (1999) from the National Doping Control Center and a bachelor’s degree in Pharmacy (1996) from Peking University in China. Dr. Wang is an Adjunct Professor at the University of Florida, Beijing University, Shanghai University of Traditional Chinese Medicine, and Central South University. Dr. Wang has published over 120 papers and given over 500 presentations at various national and international meetings as an expert in new drug development and regulation. He was selected to be one of the top Healthcare Technology Leaders of Washington, DC for 2023. He is the external advisor for the Chinese National Medical Products Administration and the expert reviewer for the Chinese Ministry of Science and Technology. He also serves as an expert advisor for Shanghai Free Trade Zone Fund and a senior consultant to multiple American investment companies and banks.

Yi Wang is a Partner at Legend Star, where he leverages emerging technologies to address unmet medical needs and unlock health-economic value. Specializing in early-stage venture incubation, he focuses on the intelligent and robotic transformation of medical devices and has played a pivotal role in the growth of innovative companies such as Edge Medical, Longwood Valley MedTech, DeepWise, Union Strong and Healinno Tech. Prior to Legend Star, Yi held business-development and clinical-translation roles at global medicare firms including Johnson & Johnson and 3M. 

Wang Yu is the chairman of the China Foundation for Hepatitis Prevention and Control. He received his M.D. from Beijing Medical University and Ph.D. from Japan Jichi Medical University. He has a professional background in viral molecular biology and immunology and has been engaged in research on hepatitis viruses and related diseases. He has successively served as the Director of the Hepatology Institute of Beijing Medical University, the Vice President of Beijing Medical University, the Deputy Director of the China National Biotechnology Development Center, and the Deputy Director of the Department of Rural and Social Development of the Ministry of Science and Technology. From 2004 to 2017, he served as the director General of the Chinese Center for Disease Control and Prevention. He is currently an executive director of the Chinese Medical Association, a member of the Expert Advisory Committee of the National Immunization Program, and a member of the World Health Organization’s Western Pacific Region Polio Eradication Certification Committee.

WEI Wensheng received his bachelor’s degree in Biochemistry from Peking University and a Ph.D. in Genetics from Michigan State University. After postdoctoral training and working as a research associate at Stanford University School of Medicine, Dr. Wei became a principal investigator in the School of Life Sciences at Peking University from 2007. He is currently a professor at the Biomedical Pioneering Innovation Center, Peking-Tsinghua Center for Life Sciences, and the School of Life Sciences at Peking University, Director of the Genome Editing Research Center at Peking University, and Lead Scientist at Changping Laboratory. The Wei group’s research primarily focuses on advancing eukaryotic gene editing tools, with particular emphasis on high-throughput functional genomics, gene and cell therapy, and innovative RNA therapeutics utilizing circular RNAs.　

Dr. Ziping Wei is co-founder, Chairman, and Chief Executive Officer of BlissBio, which is a clinical stage company focusing on the development of ADC products. She has had over twenty years of industrial experience in biopharmaceutical development and commercialization in the US. She served in CMC development at Novavax, Medimmune-AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson. She contributed to the development of over 40 antibodies and vaccine products, including therapeutic monoclonal antibodies, bispecific antibodies, ADCs, recombinant proteins, and virus vaccine, of which 9 were approved to the market. Dr. Wei is a former president of Chinese Biopharmaceutical Association-USA. She received her Ph.D. in Chemistry at Rutgers, the State University of New Jersey, and B.S. in Chemistry at the University of Science and Technology of China.

Prof. Wong holds a Bachelor of Science (BSc) and a PhD in Biochemistry from the University of Hong Kong. He is currently a principal investigator at the School of Chinese Medicine, Hong Kong Baptist University, where he leads a multidisciplinary team specializing in biology, neuroscience, and microbiome research.

Collaborating closely with clinicians and bioinformaticians, Prof. Wong’s laboratory has achieved multiple groundbreaking discoveries in drug discovery for metabolic disorders, leading to high-impact publications as first or corresponding author in journals such as Nature Communications, Cell Host & Microbe, Nature Metabolism, and Developmental Cell.

In recognition of research excellence, Prof. Wong has received several prestigious awards, including the School Performance Award as Young Researcher (2021), the President’s Award for Outstanding Performance as an Early Career Researcher (2022), and the National Natural Science Foundation of China (NSFC) Excellent Young Scientist Fund (Hong Kong and Macau, 2023). As principal investigator, he has secured over HK$20 million in competitive research funding from Hong Kong, Europe, and Mainland China to support his multidisciplinary translational research program.

Dr. Chengbin Wu is the founder and Chief Executive Officer of EpimAb Biotherapeutics Inc., an innovative, clinical-stage biologics company focusing on developing next generation antibody-based therapies for oncology and other areas of high unmet medical needs. Dr. Wu has over 20 years of experience in discovery, development, and technological innovation in the antibody field, and he is a world renowned expert in bispecific antibody technologies and therapeutic development. Dr. Wu has built a distinguished career in the biopharmaceutical industry, taking on different leadership responsibilities in different parts of the world. Previously he was Chief Scientific Officer and President of R&D at Shanghai CP Guojian Pharmaceutical Co., a leading China-based biopharmaceutical company. Before that he was the Senior Vice President Biologics at Shanghai ChemPartner, where he established a comprehensive antibody R&D platform. Prior to returning to China, Dr. Wu was a Volwiler Associate Fellow at Abbott Laboratories, where he led several novel biologics projects from concept to regulatory filing. Dr. Wu received his Ph.D. degree from the University of Georgia in the US, and postdoctoral fellowship at Harvard Medical School with a grant from the Cancer Research Institute.

Dr. Xie Xuanhui serves as the Chief Innovation and Investment Officer at IASO Bio, where he is responsible for spearheading the incubation and investment of innovative businesses, with a focus on the upstream and downstream incubation of the cell and gene therapy (CGT) industry chain. Prior to joining IASO Bio, Dr. Xie, as a co-founder, successfully incubated and invested in a gene engineering vector vaccine platform. This platform established multiple product lines targeting the markets of economic animals and pets, as well as human vaccines, aiming to meet the demands of import substitution and industrial upgrading. He also co-founded a synthetic biology platform, which set up several product lines in various fields including agriculture, medical aesthetics, and functional foods, exploring the innovative growth potential of biotechnology beyond the pharmaceutical sector. Additionally, Dr. Xie, as a co-founder, incubated several cutting-edge technology platforms including mRNA, siRNA, and phage therapy. During his tenure as a founding partner at TVM Capital China, Dr. Xie focused on cross-border equity investment and technology transfer in the field of innovative drugs, committed to introducing international advanced pharmaceutical technologies and investment concepts to the Chinese market, and promoting the innovative development of China’s pharmaceutical industry.

Kevin Xu is currently serving as the Chairman & CEO of ClinChoice Medical Development Ltd – a global clinical stage CRO powering biotech innovation across US, China, EU and other APAC markets with end-to-end clinical development solutions. Previously, Kevin was a Managing Director at Goldman Sachs, where he built and led the firm’s Asia-Pacific Healthcare & Life Science Investing business for over 15 years. During his tenure, he directed high-impact investments across biotech, pharma, medtech, CROs/CDMOs, digital health, and AI-driven life science platforms, backing industry-leading innovators. Kevin holds an MSc in Neuroscience and Clinical Psychology from King’s College London’s Institute of Psychiatry, Psychology & Neuroscience, a Master of Finance from the University of Cambridge, and a B.S. from the University of Maryland. He also serves as the Queens’ Alumni Ambassador for Strategic Partnerships at the University of Cambridge. and a B.S. from the University of Maryland. He also serves as the Queens’ Alumni Ambassador for Strategic Partnerships at the University of Cambridge.

Dr. Xu is an industry expert with a unique blend of academic expertise in biocomputing and business acumen. She holds a Bachelor’s degree in Pharmacy from Fudan University and a Ph.D. in Computational Chemistry from The University of Hong Kong. As a founding member of BioMap, Dr. Xu has led multiple core initiatives ranging from AI product strategy and innovative R&D to project incubation and strategic investments. She has spearheaded her team in driving deep integration and innovation between biotechnology and computational technologies, resulting in a series of internationally acclaimed foundation model advancements in life sciences.